Clinical Trials for Plus Therapeutics

Explore 5 clinical trials worldwide

Showing 1-5 of 5 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: Plus Therapeutics

Clinical Trials (5)

NCT07061626
Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma
PHASE1Not yet recruiting
56 participants
Started: Sep 30, 2025 · Completed: Mar 31, 2027
2 conditions2 sponsors0 locations
NCT07098806
Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases
PHASE1Recruiting
24 participants
Started: Jul 2, 2025 · Completed: Oct 2, 2031
1 condition1 sponsor1 location
NCT05460507
Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment
PHASE1Recruiting
40 participants
Started: Dec 12, 2024 · Completed: Mar 1, 2028
1 condition1 sponsor1 location
NCT05034497
Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases
PHASE1Active, not recruiting
18 participants
Started: Dec 6, 2021 · Completed: Jun 30, 2026
1 condition1 sponsor6 locations
NCT01906385
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
PHASE1/PHASE2Recruiting
55 participants
Started: Jun 3, 2015 · Completed: Dec 31, 2025
1 condition2 sponsors3 locations